U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328971) titled 'Vancomycin Taper to Prevent Recurrent Clostridioides Difficile' on Nov. 25, 2025.
Brief Summary: Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial is:
1) For first episodes and first recurrences of CDI, to test whether a vancomycin P-T is non-inferior to 10-days of fidaxomicin for the prevention of rCDI at 56 days
Study Start Date: June 01, 2026
Study Type: INTERVENTIONAL
Condition:
Clostridia Difficile...